What is Opus Ksd?
Opus Ksd, Inc. is at the forefront of developing advanced surgical closure solutions, most notably its SubQ It! bioabsorbable skin closure system. This disposable stapler is engineered for the subcutaneous closure of small and laparoscopic incisions, offering a substantial improvement over traditional suturing methods. The SubQ It! system facilitates wound closure up to seven times faster than conventional techniques, while simultaneously mitigating patient discomfort and eliminating the need for post-operative staple removal. Having achieved FDA clearance, the product is specifically tailored for minimally invasive surgery applications, positioning Opus Ksd as a key innovator in a rapidly evolving surgical landscape. The company's focus on reducing scarring and ensuring efficient, rapid incision closure highlights its commitment to enhancing patient outcomes and surgical efficiency.
How much funding has Opus Ksd raised?
Opus Ksd has raised a total of $500K across 1 funding round:
Private Equity
$500K
Private Equity (2016): $500K, investors not publicly disclosed
What's next for Opus Ksd?
With the recent major strategic investment, Opus Ksd is well-positioned to accelerate its market penetration and further scale its operations. The substantial capital infusion, indicated by the $500K total funding, suggests a trajectory towards broader adoption of the SubQ It! system in surgical centers and hospitals. This strategic financing is likely to fuel expanded manufacturing capabilities, enhanced sales and marketing initiatives, and continued research and development to solidify its competitive advantage in the minimally invasive surgery market. The company's focus on FDA-cleared, high-impact medical devices points to a future of sustained growth and innovation in surgical technology.
See full Opus Ksd company page
